The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice

• Philippe Gallay ,

  Contributed equally to this work with: Philippe Gallay, Daren Ure

  Roles Conceptualization, Investigation, Methodology, Supervision, Validation, Visualization, Writing – original draft

  * E-mail: gallay@scripps.edu (PG); rfoster@contravir.com (RF); dure@contravir.com (DU)

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  http://orcid.org/0000-0002-6151-4764

  ⨯
• Daren Ure ,

  Contributed equally to this work with: Philippe Gallay, Daren Ure

  Roles Writing – review & editing

  * E-mail: gallay@scripps.edu (PG); rfoster@contravir.com (RF); dure@contravir.com (DU)

  Affiliation ContraVir Pharmaceuticals Inc., Edison, New Jersey, United States of America

  ⨯
• Michael Bobardt,

  Roles Investigation, Methodology

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• Udayan Chatterji,

  Roles Investigation, Methodology

  Affiliation Department of Immunology & Microbiology, The Scripps Research Institute, La Jolla, California, United States of America

  ⨯
• James Ou,

  Roles Methodology, Resources

  Affiliation Department of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles, California, United States of America

  http://orcid.org/0000-0002-8274-5705

  ⨯
• Daniel Trepanier,

  Roles Investigation, Methodology, Writing – review & editing

  Affiliation ContraVir Pharmaceuticals Inc., Edison, New Jersey, United States of America

  ⨯
• Robert Foster

  Roles Conceptualization, Investigation, Resources, Supervision, Writing – review & editing

  * E-mail: gallay@scripps.edu (PG); rfoster@contravir.com (RF); dure@contravir.com (DU)

  Affiliation ContraVir Pharmaceuticals Inc., Edison, New Jersey, United States of America

  ⨯